Skip to main content
. 2015 Dec 5;7(2):1741–1753. doi: 10.18632/oncotarget.6480

Figure 1. Counts of viable breast cancer cells after administration of PB and trastuzumab.

Figure 1

A. Counts of viable cells after 7 days of PB administration compared to control cells. B. Counts of viable cells after administration of lower PB doses (0.5-fold dosage at 0.25mM and 0.25-fold dosage at 0.125mM) in PB-sensitive cells as compared to PB-resistant cells. C. Counts of viable cells after PB administration compared to trastuzumab administration.